Kárai Bettina, Hevessy Zsuzsanna, Szánthó Eszter, Csáthy László, Ujfalusi Anikó, Gyurina Katalin, Szegedi István, Kappelmayer János, Kiss Csongor
Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt 98, Debrecen, 4032, Hungary.
Department of Pediatric Hematology and Oncology, Institute of Pediatrics, Faculty of Medicine, University of Debrecen, Nagyerdei krt 98, Debrecen, H-4032, Hungary.
Pathol Oncol Res. 2018 Apr;24(2):345-352. doi: 10.1007/s12253-017-0236-0. Epub 2017 May 18.
Previously we identified B-cell lineage leukemic lymphoblasts as a new expression site for subunit A of blood coagulation factor XIII (FXIII-A). On the basis of FXIII-A expression, various subgroups of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) can be identified. Fifty-five children with BCP-ALL were included in the study. Bone marrow samples were obtained by aspiration and the presence of FXIII-A was detected by flow cytometry. G-banding and fluorescent in situ hybridization was performed according to standard procedures. The 10-year event-free survival (EFS) and overall survival (OS) rate of FXIII-A-positive and FXIII-A-negative patients showed significant differences (EFS: 84% vs. 61%, respectively; p = 0.031; OS: 89% vs. 61%; p = 0.008). Of all the parameters examined, there was correlation only between FXIII-A expression and 'B-other' genetic subgroup. Further multivariate Cox regression analysis of FXIII-subtype and genetic group or 'B-other' subgroup identified the FXIII-A negative characteristic as an independent factor associated with poor outcome in BCP-ALL. We found an excellent correlation between long-term survival and the FXIII-A-positive phenotype of BCP lymphoblasts at presentation. The results presented seem to be convincing enough to suggest a possible role for FXIII-A expression in the prognostic grouping of childhood BCP-ALL patients.
此前我们鉴定出B细胞系白血病淋巴母细胞是凝血因子XIII亚基A(FXIII-A)的一个新表达位点。基于FXIII-A的表达情况,可鉴定出B细胞前体急性淋巴细胞白血病(BCP-ALL)的不同亚组。55例BCP-ALL患儿纳入本研究。通过骨髓穿刺获取骨髓样本,采用流式细胞术检测FXIII-A的表达情况。按照标准程序进行G显带和荧光原位杂交。FXIII-A阳性和阴性患者的10年无事件生存率(EFS)和总生存率(OS)存在显著差异(EFS:分别为84%和61%;p = 0.031;OS:89%和61%;p = 0.008)。在所有检测参数中,仅FXIII-A表达与“B-其他”基因亚组之间存在相关性。对FXIII亚型与基因组或“B-其他”亚组进行进一步的多因素Cox回归分析,确定FXIII-A阴性特征是BCP-ALL预后不良的一个独立相关因素。我们发现初诊时BCP淋巴母细胞的长期生存与FXIII-A阳性表型之间存在良好的相关性。所呈现的结果似乎足以令人信服地表明FXIII-A表达在儿童BCP-ALL患者预后分组中可能发挥的作用。